CABG remains the main stay treatment for triple vessel disease. Not only it helps revascularisation but also prevents MI, thus increasing lifespan.                                            Team@CMHF

Coronary artery bypass grafting (CABG), a modern and safe procedure, is considered the therapy of choice in the care of patients with multi-vessel disease.

The 3-year results of the SYNTAX trial not only showed surgical advantages in terms of repeat revascularisation, but the results also demonstrated significant surgical benefit for myocardial infarction and survival rates.

PCI tends to be a comparable therapeutic option only in certain cases of left main stem lesions or multi-vessel disease.

Reference:http://www.docguide.com/modern-coronary-surgery-syntax-trial-and-updated-guidelines?tsid=5